Skip to content

Evaluation for the effect of case management for pregnant patients with diabetes with the blood glucose monitoring system based on the cloud platform was used to evaluate the effect of case management for pregnant patients with diabetes

Evaluation for the effect of case management for pregnant patients with diabetes with the blood glucose monitoring system based on the cloud platform was used to evaluate the effect of case management for pregnant patients with diabetes

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022299
Enrollment
Unknown
Registered
2019-04-03
Start date
2019-04-02
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Pregnancy with diabetes:specialized guidance

Sponsors

Second Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Able to understand the purpose of clinical trials, willing to participate and sign informed consent; 2. Female aged 25-40 years; 3. Patients with type 2 diabetes were definitely diagnosed according to WHO diagnostic criteria; 4. Pregnancy was confirmed for 3 months by detection of Human chorionic gonadotropin (HCG) in venous blood; 5. Can regularly use insulin to reduce blood glucose, and control blood glucose with diabetic diet and exercise; 6. Willing and able to use CareSens N Premier glycemic meter for fingertip blood glucose monitoring as required 7. The patient is equipped with a smartphone with android or IOS operating system and can understand and master the smart tube Manage the application method of the system APP, and upload the results using the mobile terminal; 8. Be able to follow the insulin treatment plan and diabetes diet determined by the researcher.

Exclusion criteria

Exclusion criteria: 1. Moderate to severe anemia: hemoglobin 90g/L; 2. Known allergy to insulin, insulin analogues or ingredients in their preparations; 3. Severe diabetic complications such as severe ketosis or ketoacidosis occurred in the first 3 months of screening; 4. Uncontrolled hypoglycemia or hyperglycemia, insulin dose adjustment fails to produce appropriate efficacy (study) Doctor's judgment); 5. Have received or are receiving systemic hormones, immunosuppressive agents and other treatments within 3 months before screening; 6. High-risk pregnancy (preeclampsia, preeclampsia, eclampsia, placenta previa, placental abruption, etc.) 7, serious systemic diseases (cardiovascular system, respiratory system, digestive system, nervous system, gai Urinary reproductive system, blood system, malignant tumor or mental disease; 8. Patients with abnormal pregnancy history: history of multiple or habitual abortion, stillbirth, stillbirth and newborn Death history, etc. 9. History of drug or alcohol abuse or dependence; 10. Poor compliance, failure to complete the test as required, or other reasons are not suitable for participation (study) by Doctor's judgment).

Design outcomes

Primary

MeasureTime frame
HbA1C;peripheral Fasting blood glucose;Peripheral postprandial blood glucose;FPG;PPG;

Countries

China

Contacts

Public ContactYang Maoguang

Second Hospital of Jilin University

154633695@qq.com+86 13664431161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026